Zipalertinib Demonstrates Clinically Meaningful Intracranial Antitumor Activity in Patients with NSCLC with EGFR Exon 20 Insertion or Uncommon EGFR Mutations and Active CNS MetastasesBusiness Wire · 5 days ago
Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewsWire · Oct 8, 2026
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review ProgramGlobeNewsWire · Oct 1, 2026
Cullinan Therapeutics: Compelling Pullback For CLN-978's Potential In Autoimmune DiseasesSeeking Alpha · Sep 29, 2026
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049MarketBeat · Sep 28, 2026
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager PortfolioGlobeNewsWire · Sep 24, 2026Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.80 | -$0.81 | Miss |
| May 7, 2026 | -$0.84 | -$0.75 | Beat |
| Mar 10, 2026 | -$0.80 | -$0.77 | Beat |
| Nov 6, 2025 | -$0.95 | -$0.77 | Beat |
| Aug 7, 2025 | -$0.83 | -$1.07 | Miss |
| May 8, 2025 | -$0.78 | -$0.74 | Beat |